CDEK
← All drugs Report issue

angiotensin 1-7

Peptideexperimental

Angiotensinamide is octapeptide amide of bovine angiotensin II used to increase blood pressure by vasoconstriction. Angiotensinamide is indicated for the treatment of severe hypotension unresponsive to traditional pressor agents. Angiotensinamide has a strong pressure effect, due to the increased peripheral resistance of blood vessels, especially small caliber arterioles. Under the influence of angiotensinamide, the vessels of the internal organs, skin, kidneys are particularly narrowed. Blood circulation in skeletal muscles and coronary vessels does not change significantly. The drug has no direct effect on the heart and does not cause arrhythmias in therapeutic doses. Angiotensinamide is rapidly inactivated by enzymes contained in the blood, and therefore, when administered once, it has a short-term (2–3 min) pressure effect. However, the duration of the effect can be relatively easily controlled by selecting the appropriate rate of administration of the drug solution. — NCATS

Clinical trial activity

36 trials · 29 clinical orgs · 0 marketing orgs

Phase 1
20
Phase 2
17
Phase 3
2
Phase 4
0

Earliest trial started Mar 1, 2007 (NCT00471562)

Timeline

2000s

  1. Jan 1, 2007

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2008

    Earliest Phase 2 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N1CCC[C@H]1C(=O)O
Mol. weight
899.02 g/mol
Lipinski Ro5
3 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • ang i (1-7)
  • angiotensin (1-7)
  • angiotensin (1-7)
  • angiotensin (1-7)
  • angiotensin 1-7
  • angiotensin 1-7
  • angiotensin-(1-7)
  • angiotensin-(1-7)
  • angiotensin-(1-7)
  • angiotensinamide
  • angiotensinamide
  • angiotensinamide
  • angiotensin i (1-7)
  • angiotensin-i (1-7)
  • angiotensin ii (1-7)
  • angiotensin ii-(1-7)
  • angiotensin ii (1-7) heptapeptide
  • gi heptapeptide
  • txa127
  • txa127
  • txa127
  • txa-127
  • txa-127

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06482853Early Phase 1 (Phase 1)Dec 31, 2024National Heart, Lung, and Blood Institute (NHLBI), Pennsylvania State University
NCT06282965Phase 1/Phase 2 (Phase 2)May 28, 2024Department of Defense, University of Arizona
NCT06135103Phase 2Nov 26, 2023Constant Pharmaceuticals
NCT06013839Phase 2Aug 31, 2023Constant Pharmaceuticals
NCT05301192Early Phase 1 (Phase 1)Oct 5, 2022National Heart, Lung, and Blood Institute (NHLBI), Pennsylvania State University
NCT05336175Phase 1/Phase 2 (Phase 2)Apr 30, 2022University of Arizona
NCT04778059Phase 2Jul 27, 2021University of Arizona, US Biotest
NCT04924660Phase 2/Phase 3 (Phase 3)Jul 15, 2021National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Vanderbilt University
NCT04570501Phase 1/Phase 2 (Phase 2)Jan 31, 2021Stanford University
NCT04605887Phase 2Nov 30, 2020Constant Pharmaceuticals, Technion University
NCT04633772Phase 1/Phase 2 (Phase 2)Aug 5, 2020Angitec, Angitex, Erasmus University Rotterdam, Federal University of Minas Gerais, Fonds Erasme pour la Recherche Medicale
NCT04401423Phase 2Jun 30, 2020Columbia University
NCT04375124N/AApr 25, 2020Kanuni Sultan Suleyman Training and Research Hospital
NCT04332666Phase 2/Phase 3 (Phase 3)Mar 31, 2020Erasmus University Rotterdam, Federal University of Minas Gerais
NCT03777215Early Phase 1 (Phase 1)Jul 31, 2019Pennsylvania State University
NCT03604289Early Phase 1 (Phase 1)Sep 30, 2018American Heart Association, Pennsylvania State University
NCT03240068Early Phase 1 (Phase 1)Sep 1, 2017Pennsylvania State University
NCT03252093Phase 2Jul 20, 2017National Institutes of Health (NIH), Suburban Hospital, University of Arizona
NCT03159988Phase 2Apr 30, 2016University of Arizona
NCT02646475Phase 1Feb 1, 2016Vanderbilt University
Showing 20 of 36 trials
Page 1 / 2

Organizations

Research & Development (29)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Constant PharmaceuticalsFor profit121022008
Pennsylvania State UniversityAcademic/Hospital5512017
University of ArizonaAcademic/Hospital5412016
US BiotestFor profit5222008
Vanderbilt UniversityAcademic/Hospital4422014
National Heart, Lung, and Blood Institute (NHLBI)Government3022021
Erasmus University RotterdamAcademic/Hospital2222020
Federal University of Minas GeraisAcademic/Hospital2022020
National Cancer Institute (NCI)Government2022007
National Institutes of Health (NIH)Government2022017
University of MichiganAcademic/Hospital2212011
Wake Forest UniversityAcademic/Hospital2222007
American Heart AssociationAcademic/Hospital1012018
AngitecFor profit1012020
AngitexFor profit1012020
Columbia UniversityAcademic/Hospital1112020
Department of DefenseGovernment1012024
Duke UniversityAcademic/Hospital1012012
Emory UniversityAcademic/Hospital1012013
Federal University of Rio Grande do SulAcademic/Hospital1112014
29 organizations
Page 1 / 2